MX9801149A - Metansulfonato de (1s,2s)-1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-1-i l)-1-propanol trihidratado y uso del mismo. - Google Patents

Metansulfonato de (1s,2s)-1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-1-i l)-1-propanol trihidratado y uso del mismo.

Info

Publication number
MX9801149A
MX9801149A MX9801149A MX9801149A MX9801149A MX 9801149 A MX9801149 A MX 9801149A MX 9801149 A MX9801149 A MX 9801149A MX 9801149 A MX9801149 A MX 9801149A MX 9801149 A MX9801149 A MX 9801149A
Authority
MX
Mexico
Prior art keywords
phenylpiperidin
trihydrate
hydroxyphenyl
hydroxy
propanolmethanesulfonate
Prior art date
Application number
MX9801149A
Other languages
English (en)
Other versions
MXPA98001149A (es
Inventor
Marta M Andino
Terry G Sinay
Eugene F Fiese
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX9801149A publication Critical patent/MX9801149A/es
Publication of MXPA98001149A publication Critical patent/MXPA98001149A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/52Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Esta invencion se refiere a la sal de mesilato de (15, 25)-1-(hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin -1-il)-1-propanol trihidratado, a composiciones farmacéuticas que la contengan y a su uso para preparar composiciones para el tratamiento de enfermedades del SNC.
MXPA/A/1998/001149A 1995-08-11 1998-02-10 Metansulfonato de (1s,2s)-1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-1-il)-1-propanoltrihidratado y uso del mismo MXPA98001149A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US223895P 1995-08-11 1995-08-11
US002238 1995-08-11
PCT/IB1996/000592 WO1997007098A1 (en) 1995-08-11 1996-06-20 (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate trihydrate

Publications (2)

Publication Number Publication Date
MX9801149A true MX9801149A (es) 1998-05-31
MXPA98001149A MXPA98001149A (es) 1998-10-23

Family

ID=

Also Published As

Publication number Publication date
AU5908496A (en) 1997-03-12
NO310458B1 (no) 2001-07-09
DK0843661T3 (da) 2002-07-22
JP3099072B2 (ja) 2000-10-16
EP0843661B1 (en) 2002-03-27
IL122649A0 (en) 1998-08-16
TNSN96104A1 (fr) 2005-03-15
IS4643A (is) 1997-12-30
CO4750830A1 (es) 1999-03-31
WO1997007098A1 (en) 1997-02-27
ATE215072T1 (de) 2002-04-15
HRP960372B1 (en) 2003-04-30
RS49521B (sr) 2006-10-27
KR100291882B1 (ko) 2001-10-26
CN1615861A (zh) 2005-05-18
CA2228752A1 (en) 1997-02-27
IL122649A (en) 2001-08-26
CN1198739A (zh) 1998-11-11
HRP960372A2 (en) 1998-04-30
IS1945B (is) 2004-08-13
ES2170857T3 (es) 2002-08-16
EP0843661A1 (en) 1998-05-27
DE69620191D1 (de) 2002-05-02
AU710984B2 (en) 1999-10-07
HUP9802862A2 (hu) 1999-04-28
RO120134B1 (ro) 2005-09-30
PL325050A1 (en) 1998-07-06
AP755A (en) 1999-08-02
JPH10510552A (ja) 1998-10-13
BR9610766A (pt) 1999-07-13
AP9600856A0 (en) 1996-10-31
DZ2083A1 (fr) 2002-10-23
PL185603B1 (pl) 2003-06-30
ZA966760B (en) 1998-02-09
BG63678B1 (bg) 2002-09-30
MA23957A1 (fr) 1997-04-01
GT199600051A (es) 1997-12-26
DE69620191T2 (de) 2002-07-18
PT843661E (pt) 2002-07-31
SK16698A3 (en) 1999-06-11
HUP9802862A3 (en) 1999-05-28
RU2140910C1 (ru) 1999-11-10
PE4898A1 (es) 1998-03-16
TW495502B (en) 2002-07-21
US6008233A (en) 1999-12-28
KR19990036321A (ko) 1999-05-25
NO980574D0 (no) 1998-02-10
TR199800208T1 (es) 1998-05-21
YU46196A (sh) 1999-07-28
CZ296236B6 (cs) 2006-02-15
NZ309134A (en) 1999-09-29
SA96170171B1 (ar) 2006-05-20
NO980574L (no) 1998-02-10
UA59341C2 (uk) 2003-09-15
CA2228752C (en) 2002-12-10
AR004676A1 (es) 1999-03-10
OA10664A (en) 2000-11-06
SK284209B6 (en) 2004-11-03
BG102289A (en) 1998-09-30
CZ39098A3 (cs) 1999-02-17

Similar Documents

Publication Publication Date Title
CA2228752A1 (en) (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate
MX9706969A (es) 3-(1,2,3,6-tetrahidropiridin-4-il)-1h-indoles y 3-(piperidin-4-il)-1h-indoles sustituidos en la posicion 5: agonistas del 5-ht1f novedosos.
EP0686629A3 (en) Cyclohexyl tachykinine receptor antagonists
PL314487A1 (en) Non-peptidic antagonists of tachykinin receptors
BG102726A (en) Combined therapy for osteoporosis
IL115156A (en) Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
DE69626660D1 (en) 2-alkylpyrrolidine
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
MY129293A (en) The use of mmp-13 selective inhibitors for the treatment of osteoarthristis and other mmp-mediated disorders
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
BG102690A (en) Il-8 receptor antagonists
SI0725779T1 (es)
BG105534A (en) 5ht1 means and method for the treatment of migraine
ZA965235B (en) Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders
IL112895A (en) Pharmaceutical compositions for the treatment of obsessive-compulsive disorders comprising 5-HT2 antagonists
AU1753699A (en) Application of vasopressin antagonists for treating disturbances or illnesses ofthe inner ear
YU13301A (sh) Muskarinski agonisti i antagonisti
EP1032556A4 (en) PHARMACEUTICALLY EFFECTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
NZ331683A (en) New indole and indazole compounds, a process for their preparation and pharmaceutical compositions containing them
IE822811L (en) (+)-2-£1-(2,6-dichlorophenoxy)-ethyl|-1,¹3-diazacyclopent-2-ene
BG104038A (en) Use of specific antagonist of 5ht2 receptors for preparing medicines useful for treating sleep-disordered breathing
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
HUP0000110A3 (en) Pharmaceutical compositions comprising azacyclic, azabicyclic or tetrahydro-pyridine-derivatives suitable for treating pain

Legal Events

Date Code Title Description
FG Grant or registration